Regeneron Pharmaceuticals Inc. (REGN)

367.64
NASDAQ : Health Technology
Prev Close 366.43
Day Low/High 364.66 / 370.14
52 Wk Low/High 281.89 / 526.12
Avg Volume 859.50K
Exchange NASDAQ
Shares Outstanding 105.95M
Market Cap 39.52B
EPS 11.30
P/E Ratio 29.69
Div & Yield N.A. (N.A)

Latest News

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Tuesday 6/26/18)

How to Invest at Every Age: Cramer's 'Mad Money' Recap (Tuesday 6/26/18)

Jim Cramer looks at the investment strategies you and your family need to employ throughout your life.

Kraft Heinz, VF Corp, Cimarex Energy: 'Mad Money' Lightning Round

Kraft Heinz, VF Corp, Cimarex Energy: 'Mad Money' Lightning Round

Jim Cramer takes a look at Kraft Heinz, VF Corp, Cimarex Energy, STORE Capital, Wheaton Precious Metals, Bluebird Bio, First Commonwealth Financial Corp.

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Jim Cramer says many stocks already reflect the worst-case scenarios, and that means he sees a lot of upside potential.

Regeneron Is Leading the Way for Biotech

Regeneron Is Leading the Way for Biotech

Recent action tells us REGN's momentum is super strong.

Chart of the Day: Regeneron

Wednesday’s action tells us REGN’s momentum is super strong.

Regeneron Pharmaceuticals Becomes #47 Most Shorted Nasdaq 100 Component, Replacing Texas Instruments

Regeneron Pharmaceuticals Becomes #47 Most Shorted Nasdaq 100 Component, Replacing Texas Instruments

The most recent short interest data has been released for the 05/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Regeneron And Zoetis Announce Collaboration To Research Antibody Therapies For Use In Animal Health

Regeneron And Zoetis Announce Collaboration To Research Antibody Therapies For Use In Animal Health

Collaboration will also generate preclinical data to inform Regeneron's development of human medicines

Nasdaq's on Fire: Cramer's 'Mad Money' Recap (Monday 6/4/18)

Nasdaq's on Fire: Cramer's 'Mad Money' Recap (Monday 6/4/18)

Jim Cramer talks about the stocks and sectors behind the resurgence fueling the Nasdaq's gains.

Jim Cramer: Move Over FANG, Long Live INJFANG

Jim Cramer: Move Over FANG, Long Live INJFANG

The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.

Aggressive Traders Must Go Long Regeneron Pharmaceuticals

Aggressive Traders Must Go Long Regeneron Pharmaceuticals

We have more evidence to support the bull case.

Box, American Outdoor Brands, Lululemon: 'Mad Money' Lightning Round

Box, American Outdoor Brands, Lululemon: 'Mad Money' Lightning Round

Cramer weighs in on Box, American Outdoor Brands, Lululemon Athletica, Henry Schein, Regeneron Pharmeceuticals, Opko Health and more.

Trade Wars Rock Stocks: Cramer's 'Mad Money' Recap (Thursday 5/31/18)

Trade Wars Rock Stocks: Cramer's 'Mad Money' Recap (Thursday 5/31/18)

Jim Cramer says these tariffs aren't that big, but this selloff is entirely rational.

Regeneron's Investigational Ebola Treatment Shipping To Democratic Republic Of The Congo For Use In Current Outbreak

TARRYTOWN, New York, May 31, 2018 /PRNewswire/ -- Regeneron working with World Health Organization, U.

Regeneron Downtrend Ending But No Rush to Buy

Regeneron Downtrend Ending But No Rush to Buy

Stock still needs a period of base building to support advance.

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.

Regeneron Pharmaceuticals Becomes #32 Most Shorted Nasdaq 100 Component, Replacing Citrix Systems

The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Jim Cramer weighs in on Waste Management, Blackstone Group, Xilinx, Celgene, Nvidia, Exelixis, Moneygram and more.

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Jim Cramer thinks that, finally, bargain hunters are just saying, "Enough already! It can't be that bad."

12 Blue-Chip Bargains: Keep Calm and Hope for a Deeper Correction

12 Blue-Chip Bargains: Keep Calm and Hope for a Deeper Correction

Thanks to the stock market correction many world-class stocks are back down to attractive levels.

Regeneron And Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis (NASH)

Regeneron And Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis (NASH)

Collaboration based on new findings from the Regeneron Genetics Center® showing variant in HSD17B13 gene is associated with reduced risk of chronic liver diseases

Regeneron Genetics Center® Publication In New England Journal Of Medicine Identifies New Genetic Variant Providing Protection From Chronic Liver Disease

Regeneron Genetics Center® Publication In New England Journal Of Medicine Identifies New Genetic Variant Providing Protection From Chronic Liver Disease

Findings validate importance of large-scale human genetics effort undertaken by Regeneron Genetics Center; provide target for potential development of new medicines

New Opportunities in Biotech: Cramer's 'Off the Charts'

New Opportunities in Biotech: Cramer's 'Off the Charts'

The beaten down biotech sector may offer more opportunities in this newly volatile market environment.

Chopping a Way Back for the Bull: Cramer's 'Mad Money' Recap (Tuesday 3/21/18)

Chopping a Way Back for the Bull: Cramer's 'Mad Money' Recap (Tuesday 3/21/18)

Jim Cramer maps out what investors need to find a way back to the upside, including the Fed, interest rates and earnings.

EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial

EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial

Expect U.S. regulatory submission for diabetic retinopathy later this year

Walt Disney Co., RH, Immunogen: 'Mad Money' Lightning Round

Walt Disney Co., RH, Immunogen: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Walt Disney Co., RH, Immunogen, and Advanced Micro Devices.

Tech Bulls Fear China Drop: Cramer's 'Mad Money' Recap (Tuesday 3/13/18)

Tech Bulls Fear China Drop: Cramer's 'Mad Money' Recap (Tuesday 3/13/18)

In the wake of Trump's blocking the Broadcom-Qualcomm deal, Jim Cramer ask if we should be worried that all of tech that wants to be big in China could be under pressure.

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2018 With Top Awards For Novel Research On Crop Blight, Vaping And Rare Disease

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2018 With Top Awards For Novel Research On Crop Blight, Vaping And Rare Disease

Top Projects at Nation's Oldest and Most Prestigious STEM Competition for High School Seniors Have Potential Implications for Agricultural Science, Public Health and Medical Diagnosis

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2018 With Top Awards For Novel Research On Crop Blight, Vaping And Rare Disease

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2018 With Top Awards For Novel Research On Crop Blight, Vaping And Rare Disease

Top Projects at Nation's Oldest and Most Prestigious STEM Competition for High School Seniors Have Potential Implications for Agricultural Science, Public Health and Medical Diagnosis

TheStreet Quant Rating: C (Hold)